Total抗体とリン酸化抗体のCSTジャパン株式会社

Apoptosis and Autophagy

CSTコード 包装
希望納入価格(円)
国内在庫 i
2010年9月9日14時20分 現在
ご登録代理店情報 i
カスタマー情報にご登録いただいた代理店を表示しています。
ご登録代理店の変更はこちら
#6212S300 μL50,000
ログインすると国内在庫状況がご確認いただけます。

LC3B抗体製品一覧

種交差性
ヒト
特異性
LC3B タンパク質の発現を特異的に抑制します。
貯法
-20℃
社内データ

Western Blotting

Western Blotting

Western blot analysis of extracts from HeLa cells, transfected with 100 nM SignalSilence ® Control siRNA (Unconjugated) #6568 (-), SignalSilence ® LC3B siRNA I (+) or SignalSilence ® LC3B siRNA II #6213 (+), using LC3B (D11) XP™ Rabbit mAb #3868 and α-Tubulin (11H10) Rabbit mAb #2125. The LC3B (D11) XP™ Rabbit mAb confirms silencing of LC3B expression, while the α-Tubulin (11H10) Rabbit mAb is used to control for loading and specificity of LC3B siRNA.

バックグラウンド

Autophagy is a catabolic process for the autophagosomic-lysosomal degradation of bulk cytoplasmic contents (1,2). Autophagy is generally activated by conditions of nutrient deprivation but has also been associated with a number of physiological processes including development, differentiation, neurodegenerative diseases, infection and cancer (3). Autophagy marker Light Chain 3 (LC3) was originally identified as a subunit of microtubule-associated proteins 1A and 1B (termed MAP1LC3) (4), and subsequently found to contain similarity to the yeast protein Apg8/Aut7/Cvt5 critical for autophagy (5). Three human LC3 isoforms (LC3A, LC3B, and LC3C) undergo post-translational modifications during autophagy (6-9). Cleavage of LC3 at the carboxy terminus immediately following synthesis yields the cytosolic LC3-I form. During autophagy, LC3-I is converted to LC3-II through lipidation by a ubiquitin-like system involving Atg7 and Atg3 that allows for LC3 to become associated with autophagic vesicles (6-10). The presence of LC3 in autophagosomes and the conversion of LC3 to the lower migrating form LC3-II have been used as indicators of autophagy (11).

  1. Reggiori, F. and Klionsky, D.J. (2002) Eukaryot. Cell 1, 11-21.
  2. Codogno, P. and Meijer, A.J. (2005) Cell Death Differ. 12 Suppl 2, 1509-1518.
  3. Levine, B. and Yuan, J. (2005) J. Clin. Invest. 115, 2679-2688.
  4. Mann, S.S. and Hammarback, J.A. (1994) J. Biol. Chem. 269, 11492-11497.
  5. Lang, T. et al. (1998) EMBO J. 17, 3597-3607.
  6. Kabeya, Y. et al. (2000) EMBO J. 19, 5720-5728.
  7. He, H. et al. (2003) J. Biol. Chem. 278, 29278-29287.
  8. Tanida, I. et al. (2004) J. Biol. Chem. 279, 47704-47710.
  9. Wu, J. et al. (2006) Biochem. Biophys. Res. Commun. 339, 437-442.
  10. Ichimura, Y. et al. (2000) Nature 408, 488-492.
  11. Kabeya, Y. et al. (2004) J. Cell Sci. 117, 2805-2812.
使用例
製品をご使用いただいて研究を発表されましたら、ぜひお知らせください
 
関連製品
2775   LC3B Antibody
3868   LC3B (D11) XP™ Rabbit mAb
6201   SignalSilence Control siRNA (Fluorescein Conjugate)
6213   SignalSilence® LC3B siRNA II
6568   SignalSilence® Control siRNA (Unconjugated)

本製品は試験研究用です。

SignalSilence® LC3B siRNA I

Product Pathways

Tools

Applications